The popularity of Novo Nordisk’s weight-loss drugs has been ... Wegovy is only available in a handful of European countries including Germany, Denmark, Norway and Switzerland, where demand ...

Novo Nordisk has reached an agreement to buy Germany’s Cardior Pharmaceuticals for €1.025 billion ($1.1 billion), adding expertise in RNA therapeutics and a heart failure therapy in mid-stage ...

"Novo Nordisk currently charges Americans with Type 2 diabetes $969 a month for Ozempic, while this same exact drug can be purchased for just $155 in Canada and just $59 in Germany." "Novo Nordisk ...

Novo Nordisk has a dominant position in diabetes and weight-loss drugs, strong financial growth outlook, and great potential. Click to read why NVO is a Strong Buy.

Novo Nordisk hopes that new data supporting the ... The German market Over in Europe, the company also has a problem in Germany with Tresiba that could be solved with the DEVOTE data.

This summary covers recent health news, including stable pig prices in Germany, investor focus on AstraZeneca's China probe, ...

This comprehensive health news roundup highlights a tragic diphtheria case in Germany, vaccine and abortion-related scrutiny ...

Novo Nordisk, one of Europe’s leading market ... approved in the UK, Denmark, France, Germany, Norway and the US, rose by 42%. Sales of its other best-seller Ozempic, an injectable diabetes ...